# Chiron Real Estate Inc. (XRN) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Real Estate / Health Care REITs. Price $30.38, market value $440 million.

## Valuation
- **P/E (trailing): 8.2×** (5-yr avg 176.8×, 3-yr avg 304.2×). Chiron Real Estate Inc. trades at 8.2× trailing earnings, well below its own five-year average of 176.8×: cheap by its own standards. The Real Estate median in the September 2026 study was 25.2×.
- **Price / sales: 2.9×**. Each dollar of revenue is priced at 2.9×.
- **Price / book: 0.9×**. The shares trade below book value, which can signal a bargain or a balance sheet the market doubts.
- **Earnings yield: 12.2%**. The inverse of the P/E: 12.2% of the price is earned each year.

## Profitability
- **Net margin: -4.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -1.4%**. Return on equity is negative because earnings are negative.
- **Return on assets: 5.0%**. Each dollar of assets produces 5.0% of profit.

## Growth
- **Revenue growth (1 yr): 6.8%** (3-yr 2.6%/yr, 5-yr 9.6%/yr). Revenue grew 6.8% over the last year, against 9.6% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -1616.7%**. Earnings per share fell 1616.7%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 6.32%** ($2.28 per share, trailing). Chiron Real Estate Inc. yields 6.32%, high enough to check carefully: yields this high often precede a cut.
- **Dividend growth (5 yr): -3.8%/yr** (1-yr -21.4%). The dividend has not grown over five years.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover Chiron Real Estate Inc.; the consensus is buy, with an average price target of $43.13 (+42% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 5.2%** (YTD -6.3%, 3-mo -13.1%). The shares are up 5.2% over twelve months including dividends.
- **From 52-week high: -21.4%** (8.2% above the low). Trading 21% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 42**. An RSI of 42 is neutral.
- **Beta (1 yr): 0.33** (volatility 29%). Beta of 0.33 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=XRN · Page: https://foliofundamentals.com/stocks/xrn

Not investment advice.